46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04312815
(ClinicalTrials.gov)		December 28, 201716/3/2020A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTXA Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severely Active Rheumatoid Arthritis Receiving MethotrexateRheumatoid Arthritis(RA)Drug: SM03;Drug: Placebo;Drug: MTXSinoMab Pty LtdNULLRecruiting18 Years70 YearsAll510Phase 3China
2NCT04192617
(ClinicalTrials.gov)		December 31, 20145/12/2019A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving MethotrexateA Randomized,Placebo Controlled, Double-blind, Parallel Group, Phase II Study to Evaluate the Efficacy and Safety of SM03, Compared to Placebo, in Patients With Moderate-to-Severe Active Rheumatoid Arthritis Receiving MethotrexateRheumatoid ArthritisDrug: SM03;Drug: Placebo;Drug: MethotrexateSinoMab Pty LtdNULLCompleted18 Years75 YearsAll156Phase 2China
3NCT04704492
(ClinicalTrials.gov)		August 14, 20126/1/2021A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid ArthritisAn Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Preliminary Clinical Activity and Safety of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: Biological: SM03SinoMab Pty LtdNULLCompleted18 Years65 YearsAll8Phase 1China